No large randomized controlled trials have directly compared combined therapy against semaglutide monotherapy, leaving prescribers to rely on case reports and clinical judgment
In recent years, research has shown that GLP-1s may help with a variety of conditions, including obstructive sleep apnea, heart disease, and chronic kidney disease
Glucagon-Like Peptide-1 Receptor compounds that stimulate the activity of glucagon-like peptide-1 receptor
[7] Blood glucose should be monitored, and medication doses may require adjustment Skin reactions : Rash or itching has been reported in some individuals Thiamine deficiency : Chronic high-dose ALA may theoretically interfere with thiamine (vitamin B1) metabolism, particularly in individuals with alcohol use disorder [20] [21] Insulin autoimmune syndrome : Rarely, ALA has been associated with this condition causing unexpected hypoglycaemia
Learn more about each component below
Association between different GLP- 1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on the FDA adverse event reporting system database
